.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Citi
US Department of Justice
Dow
Argus Health
McKinsey
Chubb
Colorcon
Cerilliant
Merck

Generated: September 22, 2017

DrugPatentWatch Database Preview

Perflutren - Generic Drug Details

« Back to Dashboard

What are the generic sources for perflutren and what is the scope of perflutren patent protection?

Perflutren
is the generic ingredient in one branded drug marketed by Lantheus Medcl and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Perflutren has thirty-six patent family members in twenty-nine countries.

One supplier is listed for this compound.

Summary for Generic Name: perflutren

Tradenames:1
Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list28
Clinical Trials: see list14
Patent Applications: see list2,472
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:perflutren at DailyMed

Pharmacology for Ingredient: perflutren

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001RXYesYes► Subscribe► SubscribeY ► Subscribe
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001RXYesYes► Subscribe► Subscribe ► Subscribe
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: perflutren

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001► Subscribe► Subscribe
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001► Subscribe► Subscribe
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001► Subscribe► Subscribe
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001► Subscribe► Subscribe
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001► Subscribe► Subscribe
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001► Subscribe► Subscribe
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001► Subscribe► Subscribe
Lantheus Medcl
DEFINITY
perflutren
INJECTABLE;INTRAVENOUS021064-001Jul 31, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: perflutren

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,084,056Preparation of a lipid blend and a phospholipid suspension containing the lipid blend► Subscribe
8,747,892Preparation of a lipid blend and a phospholipid suspension containing the lipid blend► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: perflutren

Country Document Number Estimated Expiration
Israel137018► Subscribe
Brazil9907066► Subscribe
Norway20003471► Subscribe
South Africa9900247► Subscribe
Norway321866► Subscribe
CroatiaP990012► Subscribe
Estonia04900► Subscribe
Argentina016444► Subscribe
Eurasian Patent Organization200000765► Subscribe
Spain2336669► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: PERFLUTREN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB07/031United Kingdom► SubscribePRODUCT NAME: PERFLUTREN-CONTAINING LIPID MICROSPHERES; REGISTERED: UK EU/1/06/361/001 20060920
00267Netherlands► SubscribePRODUCT NAME: PERFLUTREN BEVATTENDE LIPIDE-MICROBOLLEN; REGISTRATION NO/DATE: EU/1/06/361/001 20060920
90017-8Sweden► SubscribePRODUCT NAME: LIPIDMIKROSFAERER INNEHALLANDE PERFLUTREN; REG. NO/DATE: EU/1/06/361/001 20060920
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Medtronic
Federal Trade Commission
US Department of Justice
Daiichi Sankyo
Citi
Julphar
QuintilesIMS
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot